<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437241</url>
  </required_header>
  <id_info>
    <org_study_id>LFL-ETR-2010-01</org_study_id>
    <nct_id>NCT01437241</nct_id>
  </id_info>
  <brief_title>Etravirine Plus 2 Analogs in HIV-infected Patients</brief_title>
  <official_title>Virological Efficacy and Safety of Etravirine Plus 2 Active Nucleos(t)Ide Reverse-transcriptase Inhibitors (NRTIs) in HIV-1-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospitales Universitarios Virgen del Rocío</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the virological and clinical efficacy of etravirine
      plus 2 active nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) in HIV-infected
      patients. Additionally, the safety of these regimens, specially lipid profiles, will be
      assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: prospective, single arm multicenter clinical trial without entry restrictions on
      plasma HIV-RNA (VL) or CD4 with a planned duration of 52 weeks.

      The primary clinical endpoint is the percentage of subjects with therapeutic success on
      etravirine 400 mg/day (200 mg bid or 400 mg qd) plus 2 active NRTIs after 12 months. Efficacy
      data will be analyzed by on-treatment and by intention-to-treat analyses (noncomplete/missing
      equals failure), considering treatment failure as either treatment interruption whatever the
      reason (adverse events, death, or loss to follow-up) or virological failure, defined as
      inability to suppress the VL to less than 50 copies/ml after 24 weeks on treatment or a
      confirmed VL of more than 200 copies/ml in patients who had previously achieved a viral
      suppression or had an undetectable viral load at inclusion.

      Patients missing two consecutive scheduled visits were considered lost to follow-up. The
      safety and tolerability of the studied medications will be evaluated by means of clinical
      adverse events, physical examination and laboratory results.

      NRTIs prescribed as part of HAART were selected by the responsible physicians on the basis of
      previous antiretroviral treatments and/or genotypic resistance testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Virological efficacy</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percentage of subjects with therapeutic success at month 12. Efficacy data will be analyzed by on-treatment and by intention-to-treat considering treatment failure as either treatment interruption whatever the reason (adverse events, death, or loss to follow-up) or virological failure, defined as inability to suppress the VL to &lt;50 copies/ml after 24 weeks or a confirmed VL of &gt;200 copies/ml in patients who had previously achieved a viral suppression or had an undetectable viral load at inclusion. Patients missing two consecutive scheduled visits were considered lost to follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>52 weeks</time_frame>
    <description>The safety and tolerability of the studied medications will be evaluated by means of clinical adverse events, physical examination and laboratory results.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">175</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>etravirine</arm_group_label>
    <description>Antiretroviral regimens based on etravirine plus 2 active nucleos(t)ide reverse-transcriptase inhibitors (NRTIs)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients who strated an antirretroviral regimen based on etravirine plus 2
        NRTIs between January 2009 and June 2010
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years, starting an antiretroviral regimen based on etravirine plus 2
             NRTIs between January 2009 and June 2010, evidence of activity of all drugs on the
             basis of treatment history and genotypic resistance testing, informed consent, and at
             least one follow-up visit.

        Exclusion Criteria:

          -  Genotypic resistance tests with evidence of resistance to any drug used, and
             concomitant use of drugs with potentially adverse interactions with etravirine
             pharmacokinetics, such as rifampin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis F Lopez-Cortes, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitales Universitarios Virgen del Rocio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Tellez-Perez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de la Linea de la Concepcion</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Vergara-Campos, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Puerto Real</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Milagros Garcia-Lazaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofia de Cordoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Hernandez-Quero, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario San Cecilio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Pascuau-Liaño, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen de las Nieves</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel A Lopez-Ruz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen de las Nieves</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed O Mohamed-Balghata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ciudad de Jaén</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr.Javier de la Torre-Lima, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Costa del Sol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Marquez Solero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Victoria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcial delgado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Carlos Haya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Lozano-León, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Valme</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital La Linea de la Concepción</name>
      <address>
        <city>La Linea de la Concepción</city>
        <state>Cadiz</state>
        <zip>11300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerto Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cadiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Malaga</state>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ciudad de Jaén</name>
      <address>
        <city>Jaen</city>
        <zip>23001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2011</study_first_posted>
  <last_update_submitted>October 30, 2011</last_update_submitted>
  <last_update_submitted_qc>October 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospitales Universitarios Virgen del Rocío</investigator_affiliation>
    <investigator_full_name>Luis F. Lopez-Cortes</investigator_full_name>
    <investigator_title>M.d., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>HIV-infection</keyword>
  <keyword>Etravirine</keyword>
  <keyword>Treatment</keyword>
  <keyword>Non-nucleoside reverse-transcriptase inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

